Overview
David Egan practices practicing medicine in Utrecht, Netherlands.
His clinical expertise encompasses Leukemoid Reaction, Acute Megakaryoblastic Leukemia, and Childhood Acute Myeloid Leukemia.
He is actively involved in clinical research, co-authoring 26 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about David A. Egan
Is David A. Egan a top-rated expert for Leukemoid Reaction?
MediFind is an objective health platform that identifies experts based on real-world data. David A. Egan is classified as an Experienced expert for Leukemoid Reaction, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does David A. Egan participate in research or clinical trials?
Yes. David A. Egan has published 26 articles and abstracts on conditions like Leukemoid Reaction. You can view a list of David A. Egan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Megakaryoblastic LeukemiaMr. Egan isExperienced. Learn about Acute Megakaryoblastic Leukemia.
- Childhood Acute Myeloid LeukemiaMr. Egan isExperienced. Learn about Childhood Acute Myeloid Leukemia.
- Leukemoid ReactionMr. Egan isExperienced. Learn about Leukemoid Reaction.